AMPLY Discovery Ltd bags £1.4m funding to tackle complex diseases
The 2021 spin-out from the Queen’s University Belfast announced it will close a seed financing round this year.vAMPLY is speeding up the discovery of...
Roche presents restistance-breaking antibiotic
Antibiotic resistance has become an urgent threat to global public health in recent decades....
SynaptixBio Ltd gets FDA ODD for leukodystrophy
Using antisense oligonucleotides (ASO) to silence the beta tubulin 4a gene, Oxford-based SynaptixBio Ltd received its first ODD in early 2023 for a...
Deregulation of new genomic techniques before decision
Although the required approval of 15 agriculture ministers was achieved in mid-December, the hotly debated proposal of the EU Commission to relax...
Curve Therapeutics raises £40.5m in Series A financing
New investors Columbus Venture Partners and British Patient Capital and founding investor Advent Life Sciences as well as seed investor Epidarex...
GLP1 agonists: FDA investigates suicide risk
It is rare for the US Food and Drug Administration (FDA) to act more slowly than its European counterpart, the EMA. However, this is the case with...
Lonza and Oxford Nanopore collaborate to advance mRNA Therapeutics
The significance of mRNA technology has been highlighted in recent years, particularly with its role in rapidly developing and bringing COVID-19...